Similarly, insurers like Health New England are ending coverage for GLP1 weightloss drugs (Saxenda, Wegovy, Zepbound) for most commercial members as of January 1, 2026, unless their employer buys an optional rider
3.Long-term ROI: tracking health outcomes, reductions in chronic conditions, and absenteeism is now table stakes
[2] Renal function tests , including serum creatinine and estimated glomerular filtration rate (eGFR), are routinely monitored at least annually, or more frequently in patients with pre-existing chronic kidney disease
Sources Glucagon-like peptide 1 and appetite (PMC, NIH) Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss (The American Journal of Medicine, ScienceDirect) How do GLP-1 medications affect appetite and digestion